Genetic liver disease
Early identification of underlying genetic cause to prevent organ damage
Identifying underlying genetic disorders plays an important role in the treatment and care of patients with liver disease. Appropriate use of screening tests in routine clinical practice can rule out possible causes of liver disease and assist in early identification and treatment of genetic liver diseases to prevent terminal organ damage.
Alpha-1-antitrypsin (A1A) deficiency
Why pay for the "gold standard" of phenotyping when it is only necessary 3% of the time?
To aid in the diagnosis of A1A deficiency, we have developed a state-of-the-art proteotype assessment that detects disease-causing variants S and Z. When physicians begin by ordering our recommended proteotyping
test, they will receive a definitive answer 97% of the time. In the other 3%, where the mass spectrometry proteotype and quantitative serum level are conflicting, phenotyping will automatically be ordered and performed.
Genetic testing to identify causative mutations may prove useful for patients suspected to have A1A deficiency, based on clinical findings or serum A1A levels, but that do not have evidence of the SZ or ZZ genotype by routine methods. Our testing performs full sequencing of the SERPINA1 coding region for the detection of rare null and non-S or non-Z disease-associated mutations.
To assist in confirming a cholestasis diagnosis, we offer a comprehensive, next-generation sequencing panel that detects variations in 112 genes associated with the condition. Used to establish molecular diagnosis, our panel identifies variants with genes known to be associated with primary, monogenic cholestasis. Results from our panel can enable predictive testing of at-risk family members.
CHLGP | Cholestasis Gene Panel, Varies
After local lab testing has identified individuals with increased transferrin-iron saturation in serum and serum ferritin, molecular testing can be done to establish or confirm the diagnosis of hereditary hemochromatosis. Our HFET gene analysis test detects the two common disease-causing mutations: C282Y and H63D. The S65C mutation is reported only when it is observed as part of the C282Y/S65C genotype.
Early diagnosis of Wilson disease allows for treatment and prevention of permanent organ damage. However, diagnosing WD can be challenging because its signs and symptoms are often hard to distinguish from those of other liver diseases, such as hepatitis. To aid clinicians, our algorithmic approach to testing ensures the right test is performed at the right time.
A variety of laboratory tests are recommended in the initial evaluation for Wilson disease, but in approximately 95% of cases, serum ceruloplasmin is below normal.
CERS | Ceruloplasmin, Serum
CUS | Copper, Serum
Copper tissue testing available, when necessary
Liver biopsy can be useful to help interpret discrepant biochemical or molecular results. Our Metals Laboratory has more than 30 years of clinical experience and a staff of 30 full-time employees.
CUT | Copper, Liver Tissue
Genetic testing to confirm diagnosis and identify at-risk family members
After initial testing, diagnosis can be confirmed through analysis of the ATP7B gene. Additionally, a confirmed genetic diagnosis enables the screening of siblings who may be able to start treatment before symptoms arise.
Lysosomal acid lipase deficiency (LAL-D)
Late-onset LAL-D is likely underdiagnosed and frequently identified after liver pathology reveals findings similar to NAFLD or NASH. Early diagnosis of LAL-D is critical to stopping the progression of the disease, as studies have shown that nearly 50% of pediatric and adult LAL-D patients progress to fibrosis, cirrhosis, or liver transplantation within three years of first clinical manifestation.
LALB | Lysosomal Acid Lipase, Blood
New guidelines recommend LAL-D be ruled out when evaluating children and adults for NAFLD
2017 NASPGHAN guidelines: Differential diagnosis for NAFLD in children
2017 AASLD guidelines: Differential diagnosis for NAFLD in adults